03.08.2012 • NewsLundbeckgenericspharmaceutical industry

Lundbeck in Deal with Teva over Copycat Antidepressant

Danish pharmaceutical group Lundbeck has agreed a deal with Israel's Teva over a copycat version of the Danish company's antidepressant drug Cipralex, it said on Thursday.

While a court injunction against copying Cipralex still stands, the parties have agreed a deal which will put an end to further court action, a Lundbeck spokesman said, while declining to give further details.

"I can confirm that we have reached a settlement but it is not a money settlement," the spokesman said.

Ratiopharm, owned by Teva, had produced copies of Cipralex while the drug was still patent protected.

Last week, EU antitrust regulators charged nine drug companies including Germany's Merck and Lundbeck with blocking the entry of a cheaper generic medicine to market.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read